| Literature DB >> 27593860 |
Woo Dae Bang1,2, Kiwoong Kim3, Yong Ho Lee3, Hyukchan Kwon3, Yongki Park3, Hui Nam Pak1, Young Guk Ko1, Moonhyoung Lee1, Boyoung Joung4.
Abstract
PURPOSE: Magnetocardiography (MCG) has been proposed as a noninvasive, diagnostic tool for risk-stratifying patients with acute myocardial infarction (AMI). This study evaluated whether MCG predicts long-term prognosis in AMI.Entities:
Keywords: Acute myocardial infarction; magnetocardiography; prognosis
Mesh:
Year: 2016 PMID: 27593860 PMCID: PMC5011264 DOI: 10.3349/ymj.2016.57.6.1339
Source DB: PubMed Journal: Yonsei Med J ISSN: 0513-5796 Impact factor: 2.759
Fig. 1Measurement of MCG. (A) MCG tracing. (B) Current vector density map. (C) Magnetic field map. Maximum current angle (C), field map angle (F), and the number and distance of poles (P) were measured every 20 ms from T-end (Te) to T-peak (Tp). MCG, magnetocardiography.
Fig. 2Examples of dipole (A) and non-dipole pattern (B). The number of poles (P) is 2 and 4 in dipole and non-dipole patterns, respectively.
Fig. 3Typical MCG finding from a 79-year-old female patient without MACE (A) and a 66-year-old female patient with MACE (B). MCG tracing (upper panels), spatiotemporal activation graph (middle panels), and magnetic field and current vector density maps (lower panels). While the dipole pattern was observed at Tp in the patient without MACE, the non-dipole pattern can be seen in the patient with MACE. Note continuous change and dispersion of the magnetic field from Tp to Te. MACE, major adverse cardiac events; MCG, magnetocardiography; Te, T-end; Tp, T-peak.
Baseline Characteristics of Study Patients
| Parameters | Total (n=124) | MACE (−) (n=93) | MACE (+) (n=31) | |
|---|---|---|---|---|
| Age, yrs | 59.8±11.3 | 59.0±11.3 | 62.1±11.4 | 0.20 |
| Sex (female), n (%) | 29 (23) | 17 (18) | 12 (39) | 0.02 |
| STEMI, n (%) | 39 (32) | 27 (29) | 12 (39) | 0.27 |
| Hypertension, n (%) | 64 (52) | 49 (53) | 15 (48) | 0.69 |
| Diabetes, n (%) | 37 (30) | 31 (33) | 6 (19) | 0.25 |
| Serum creatinine, mg/dL | 1.2±1.3 | 1.1±0.53 | 1.6±2.4 | 0.04 |
| CK, IU/L | 813.8±1199.7 | 765.5±1071.6 | 958.7±1533.4 | 0.44 |
| CK-MB, ng/mL | 206.3±156.1 | 92.4±117.3 | 147.9±235.1 | 0.09 |
| Troponin-T, ng/mL | 2.0±3.1 | 1.8±2.7 | 2.8±3.9 | 0.11 |
| LVEF, % | 52.1±13.4 | 52.4±12.8 | 51.0±15.0 | 0.59 |
| Multivessel CAD, n (%) | 79 (64) | 55 (59) | 24 (77) | 0.07 |
| Management, n (%) | ||||
| PCI | 90 (73) | 62 (67) | 28 (90) | 0.02 |
| CABG | 14 (11) | 14 (15) | 0 (0) | 0.02 |
| Medication only | 20 (16) | 17 (18) | 3 (10) | 0.40 |
| Medication, n (%) | ||||
| Antiplatelet | 121 (98) | 91 (98) | 30 (97) | 1.00 |
| Beta blocker | 92 (74) | 79 (85) | 22 (71) | 0.19 |
| ACEI or ARB | 101 (82) | 72 (77) | 20 (65) | 0.34 |
| Statin | 110 (89) | 81 (87) | 29 (94) | 0.18 |
MACE, major adverse cardiac events; STEMI, ST-elevation myocardial infarction; CK, creatine kinase; CK-MB, creatine kinase MB; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor antagonist.
Non-Dipole Patterns in Patients with or without Major Adverse Cardiac Events (MACE)
| Parameters | Total (n=124) | No MACE (n=93) | MACE (n=31) | |
|---|---|---|---|---|
| Non-dipole pattern, n (%) | ||||
| Te* | 124 (100) | 93 (100) | 31 (100) | - |
| Te-20 ms | 115 (93) | 85 (91) | 30 (97) | 0.45 |
| Te-40 ms | 89 (72) | 62 (67) | 27 (87) | 0.04 |
| Te-60 ms | 78 (63) | 53 (57) | 25 (81) | 0.02 |
| T-peak | 74 (60) | 50 (54) | 24 (77) | 0.02 |
| Maximum current angle (°) | 45.2±19.4 | 42.5±91.5 | 53.4±92.0 | 0.57 |
| Field map angle (°) | −10.9±85.9 | −11.3±83.6 | −9.64±94.0 | 0.93 |
| Pole distance, mm | 143.9±26.5 | 144.0±24.5 | 143.7±32.3 | 0.97 |
*End of T-wave.
Non-Dipole Patterns in Patients with or without Major Adverse Cardiac Events (MACE)
| Parameters | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Age, >65 yrs | 1.78 (0.88–3.62) | 0.11 | 1.22 (0.55–2.69) | 0.63 |
| Female sex | 2.67 (1.31–5.56) | 0.01 | 2.29 (1.01–5.17) | 0.05 |
| Hypertension | 0.80 (0.40–1.62) | 0.54 | 1.01 (0.46–2.22) | 0.98 |
| Diabetes | 0.53 (0.22–1.29) | 0.16 | 0.61 (0.23–1.61) | 0.32 |
| LVEF <40% | 1.19 (0.48–2.91) | 0.71 | 1.09 (0.43–2.74) | 0.85 |
| Multi-vessel CAD | 2.23 (0.94–5.18) | 0.06 | 2.19 (0.89–5.46) | 0.94 |
| STEMI | 1.39 (0.67–2.86) | 0.37 | 1.80 (0.85–3.81) | 0.12 |
| Non-dipole pattern | 2.61 (1.12–6.06) | 0.03 | 2.89 (1.20–6.97) | 0.02 |
*End of T-wave.
Fig. 4MACE-free survival. Kaplan-Meier survival curves for cardiac events in patients with different repolarization patterns at Tp. Patients with non-dipole patterns at Tp had lower cumulative cardiac event-free survival than did the dipole pattern group (p=0.02). MACE, major adverse cardiac events; Tp, T-peak.